Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: JAMA Oncol. 2016 Sep 1;2(9):1179–1186. doi: 10.1001/jamaoncol.2016.0775

Figure 3. Tumor Burden Change From First Progression.

Figure 3

Tumor burden change in target lesions from first progression in patients treated beyond progression. The horizontal dashed reference line indicates the 30% reduction consistent with a Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 response. Plus signs indicate patients who had at least 20% increase in target lesions at time of first progression. One patient did not have tumor sum of diameters values available prior to progression because 1 of the target lesions became nonmeasurable, and therefore is not shown in the Figure.